Ultrasound-Based Monitoring in Unilateral Wilms Tumor: Treatment Response Assessment and Early Relapse Dynamics (2012–2020, Single-Center Cohort)

Read full text Summarise with VIRAT
Authors: Ramin Malikov
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Abstract Background: Ultrasound-first (US-first) monitoring is commonly used in resource-variable settings to reduce radiation exposure; however, the prognostic value of neoadjuvant ultrasound response in unilateral Wilms tumor is not well defined in real-world cohorts. We assessed whether a simple dichotomized ultrasound response (regression vs non-regression) can stratify relapse and survival risk in children treated under SIOP principles. Methods: This retrospective single-center cohort included consecutive patients aged 0–18 years with unilateral Wilms tumor treated with SIOP-based protocols between 2012 and 2020 at the National Center of Oncology, Baku, Azerbaijan (n=59). Neoadjuvant response was assessed by abdominal ultrasonography using the largest axial tumor diameter and categorized as regression, stable disease, or progression (chemoresistance). For primary analyses, response was dichotomized as regression vs non-regression (stable+progression). Outcomes were relapse, overall survival (OS), and disease-free survival (DFS). Survival was estimated by the Kaplan–Meier method, and hazard ratios (HRs) were estimated using Cox regression. Results: Neoadjuvant USM response was regression in 50/59 (84.7%), stable disease in 5/59 (8.5%), and progression/chemoresistance in 4/59 (6.8%). Non-regression occurred only in stage III–IV disease (p=0.038). Over a median follow-up of 94 months, relapse occurred in 11/59 (18.6%) and death in 7/59 (11.9%); 81.8% of relapses occurred within 24 months. Relapse and death were markedly higher in the non-regression group than in the regression group (relapse 66.7% vs 10.0%; death 55.6% vs 4.0%; both p

Fields of Study & Subjects

Renal and related cancers Sarcoma Diagnosis and Treatment Testicular diseases and treatments

Publication details

Journal / source
Research Square
Publication date
23 March 2026
Language
EN
Document type
Preprint